Share purchase through non-discretionary dividend reinvestment programme of 233 shares at £11.13
Intl. Biotechnology Trust PLC
26 August 2026
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Kate Cornish-Bowden |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Director |
||||
|
b)
|
Initial notification/amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
International Biotechnology Trust plc |
||||
|
b)
|
LEI |
213800N1QUJ744P76D11 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 25 pence each ISIN: GB0004559349 |
||||
|
b)
|
Nature of the transaction |
Share purchase through non-discretionary dividend reinvestment programme |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
233 £2,593.29 |
||||
|
e) |
Date of the transaction |
25 August 2026 |
||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.